cCD79a expression in a case of plasma cell leukemia.
In the present report we analyzed the immunophenotype of the neoplastic cells in a case of primary plasma cell leukemia (PCL). We performed simultaneous analysis of bone marrow and peripheral blood samples to investigate minor phenotypic variations that could explain the tendency of a population to leave medullary compartments. No major differences were observed between the two populations. The phenotype of the malignant clone was: CD38+, CD138+, CD19-, CD56+, CD117-, CD33+, CD44 , CD49e , cCD79a+ with positive cytoplasmic stain for kappa and IgG. Our findings expands the potential uses of cCD79a to cases of PCL with atypical morphology.
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Secció de Marcadors, Barcelona, Spain.
M L
ML
Alonso
E
E
Rubiol
R
R
Mateu
C
C
Estivill
M
M
Bellido
J
J
Balmaña
J F
JF
Nomdedéu
D000368:Aged; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis*; D051925:CD79 Antigens; D003593:Cytoplasm / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D007952:Leukemia, Plasma Cell / Q000276:immunology / Q000378:metabolism*; D010950:Plasma Cells / Q000276:immunology; D011947:Receptors, Antigen, B-Cell / Q000032:analysis / Q000096:biosynthesis*
D015703:Antigens, CD; D051925:CD79 Antigens; C497881:CD79A protein, human; D011947:Receptors, Antigen, B-Cell